CL2021000196A1 - Método de tratamiento de la epilepsia - Google Patents

Método de tratamiento de la epilepsia

Info

Publication number
CL2021000196A1
CL2021000196A1 CL2021000196A CL2021000196A CL2021000196A1 CL 2021000196 A1 CL2021000196 A1 CL 2021000196A1 CL 2021000196 A CL2021000196 A CL 2021000196A CL 2021000196 A CL2021000196 A CL 2021000196A CL 2021000196 A1 CL2021000196 A1 CL 2021000196A1
Authority
CL
Chile
Prior art keywords
treatment method
epilepsy treatment
epilepsy
salt
fenfluramin
Prior art date
Application number
CL2021000196A
Other languages
English (en)
Inventor
Jeffrey Paul Bechard
Robin Paul Sherrington
Jean-Jacques Alexandre Cadieux
Parisa Karimi Tari
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CL2021000196A1 publication Critical patent/CL2021000196A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

USO DE (<em>R</em>)-FENFLURAMINA, (<em>R</em>)-NORFENFLURAMINA, (<em>R</em>)-BENFLUOREX, O UNA SAL DE LOS MISMOS PARA EL TRATAMIENTO DE LA EPILEPSIA O UN TRASTORNO CONVULSIVO; UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNO DE LOS OCMPUESTOS O SU SAL FARMACEUTICAMENTE ACEPTABLE
CL2021000196A 2018-07-27 2021-01-25 Método de tratamiento de la epilepsia CL2021000196A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27

Publications (1)

Publication Number Publication Date
CL2021000196A1 true CL2021000196A1 (es) 2021-12-31

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000196A CL2021000196A1 (es) 2018-07-27 2021-01-25 Método de tratamiento de la epilepsia

Country Status (19)

Country Link
US (1) US20200030260A1 (es)
EP (1) EP3829558A1 (es)
JP (1) JP2021530541A (es)
KR (1) KR20210061332A (es)
CN (1) CN112930175A (es)
AU (1) AU2019310600A1 (es)
BR (1) BR112021001135A2 (es)
CA (1) CA3106031A1 (es)
CL (1) CL2021000196A1 (es)
CO (1) CO2021002087A2 (es)
CR (1) CR20210095A (es)
EA (1) EA202190369A1 (es)
IL (1) IL280128A (es)
MA (1) MA53329A (es)
MX (1) MX2021000987A (es)
PE (1) PE20211065A1 (es)
PH (1) PH12021550176A1 (es)
SG (1) SG11202100682YA (es)
WO (1) WO2020023923A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
CN113499330A (zh) 2015-12-22 2021-10-15 周格尼克斯国际有限公司 芬氟拉明组合物及其制备方法
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
JP7383012B2 (ja) * 2018-08-31 2023-11-17 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物、およびナトリウムチャネル阻害剤としてのその使用
CN114127150A (zh) * 2019-07-18 2022-03-01 巴斯夫欧洲公司 脲基甲酸酯基分散剂
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023034115A1 (en) * 2021-09-01 2023-03-09 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (es) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3261640T3 (da) * 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
CN112930175A (zh) 2021-06-08
CR20210095A (es) 2021-06-01
US20200030260A1 (en) 2020-01-30
CA3106031A1 (en) 2020-01-30
PE20211065A1 (es) 2021-06-09
IL280128A (en) 2021-03-01
KR20210061332A (ko) 2021-05-27
EA202190369A1 (ru) 2021-06-10
PH12021550176A1 (en) 2021-10-11
MX2021000987A (es) 2021-06-15
WO2020023923A1 (en) 2020-01-30
CO2021002087A2 (es) 2021-04-30
JP2021530541A (ja) 2021-11-11
MA53329A (fr) 2022-03-02
SG11202100682YA (en) 2021-02-25
AU2019310600A1 (en) 2021-02-11
BR112021001135A2 (pt) 2021-04-20
EP3829558A1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
CL2021000196A1 (es) Método de tratamiento de la epilepsia
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CL2017002090A1 (es) Inhibidores selectivos de bace1
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
AR093705A1 (es) Depsipeptido y sus usos
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
UY37941A (es) Derivados de bencimidazol y sus usos
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
SV2016005313A (es) Derivados de carboxamida
CO2018001237A2 (es) Derivados de apramicina efectivos contra bacterias resistentes a múltiples fármacos y composiciones de los mismos
UY38892A (es) Moduladores de sting (estimulador de genes de interferón)
CO2022008719A2 (es) Compuestos para modular la actividad de fxr y usos de los mismos
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
BR112021026556A2 (pt) Composto tricíclico, método de preparação para ele e uso dele